Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Not Recruiting

Trial ID: NCT03391778


This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Official Title

Long-Term Follow-Up (LTFU) of Participants Treated With GSK Adoptive Cell Therapies

Stanford Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo

Professor of Medicine (Oncology)


Inclusion Criteria:

   - Participants who have received at least one dose of GSK adoptive cell therapy agent.

   - Participants who have completed GSK sponsored or supported interventional study or
   have withdrawn from it.

   - Participants who have completed treatment as part of managed access to a GSK adoptive
   cell therapy.

   - Contraceptive use by men or women should be consistent with local regulations
   regarding the methods of contraception for those participating in clinical studies.

   - The investigator is responsible for review of medical history.

   - Capable of giving signed informed consent.

Exclusion Criteria:

- None


biological: GSK adoptive cell therapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ileana Aguilar Torres

New Trial Alerts